Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

None © Shutterstock

While TLRs are receptors that detect bacteria, funghi and viruses, they are also implicated in the processes that perpetuate auto-immune diseases such as rheumatoid arthritis. In patients that failed to respond adequately to the standard treatment, there was a measurable difference in the receptors prior to treatment compared to those of patients that responded well. There was also a different profile of TLRs in the joints of rheumatoid arthritis patients compared to osteoarthritis patients. Other tissues from different stages of arthritis also showed different TLR profiles, allowing researchers to map the changes throughout the course of disease. 

Dr Clanchy, the corresponding and lead author says: "The patients that fail to respond to anti-TNF treatments have other treatment options but it would be better if we could match them to the best treatment from the beginning. Stratifying patients to the most appropriate treatment is a major challenge for rheumatoid arthritis, and finding biomarkers that sort patients to the best treatment would be helpful.”

Professor Williams continues:" This study builds on existing knowledge regarding the involvement of TLRs in rheumatoid arthritis and suggests that they could act as biomarkers to enable patient stratification."

The research was funded by in part by the MASTERSWITCH consortium (Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices) as part of the EU 7th Framework Programme, an MRC-DPFS grant and a BBSRC CASE studentship.

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.